Compare AroCell AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 76 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.24
-26.26%
0.51
Revenue and Profits:
Net Sales:
11 Million
(Quarterly Results - Sep 2025)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.39%
0%
-18.39%
6 Months
-29.35%
0%
-29.35%
1 Year
-47.41%
0%
-47.41%
2 Years
-20.22%
0%
-20.22%
3 Years
-56.97%
0%
-56.97%
4 Years
-48.27%
0%
-48.27%
5 Years
-92.62%
0%
-92.62%
AroCell AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
121.24%
EBIT Growth (5y)
-19.08%
EBIT to Interest (avg)
-49.56
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.43
Sales to Capital Employed (avg)
0.37
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.93
EV to EBIT
-0.93
EV to EBITDA
-0.93
EV to Capital Employed
0.87
EV to Sales
0.79
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-93.97%
ROE (Latest)
-49.00%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
11.40
10.10
12.87%
Operating Profit (PBDIT) excl Other Income
-2.90
-14.80
80.41%
Interest
0.10
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-3.10
-14.90
79.19%
Operating Profit Margin (Excl OI)
-259.10%
-1,461.50%
120.24%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 12.87% vs -33.99% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 79.19% vs -21.14% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
57.40
43.00
33.49%
Operating Profit (PBDIT) excl Other Income
-1.70
-14.90
88.59%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-42.40
-59.30
28.50%
Operating Profit Margin (Excl OI)
-781.30%
-1,403.70%
62.24%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 33.49% vs 16.22% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 28.50% vs 0.00% in Dec 2023
About AroCell AB 
AroCell AB
Pharmaceuticals & Biotechnology
AroCell publ AB is a Sweden-based diagnostic Company engaged in the development of markers for determination of cell growth (TK 210) and apoptosis. The Company's principal product candidate, TK-immuno/hem, is a test for monitoring and follow up of blood cancer. The test is based on a patented technology, which have already been evaluated in an early product prototype ELISA method. Apart from that, the Company develops a marker for solid tumor cancer disease. The AroCell cooperates with partners within development, production and sales.
Company Coordinates 
Company Details
Uppsala Business Park, Virdings alle 32 B UPPSALA None : 754 50
Registrar Details






